Neurocrine Biosciences

Youtube Subscribe

Open: 97.15 Close: 96.99 Change: -0.16

Don't invest before reading what an AI found about Neurocrine Biosciences Company Inc.

This document will help you to evaluate Neurocrine Biosciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, stock, price, growth, pharmaceutical, company, …

Concept Map

Semantic Network

Stock Summary

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Its products include INGREZZA and DYSVAL, for the treatment of tardive dys.

Today's Summary

64 analysts offering price forecasts for Neurocrine Biosciences have a median target of 118.42, with a high estimate of 154.00 and a low estimate of 76.00. Tardive Dyskinesia market is predicted to exhibit remarkable growth during the forecast period.

Today's News

Neurocrine Biosciences, inc. (nbix) stock price, quote & news - stock analysis. Neurocrinine Biocemes, Inc. (NBIX) Price Target $124.86 (28.74% upside) Analyst Consensus: Buy Stock Forecasts. Neurocrine Biosciences, inc. (NBIX) stock price today, quote & news. (NBX) Stock Price Today, Quote & News: nbix stock is down. 64 analysts offering price forecasts for Neurocrine Biosciences have a median target of 118.42, with a high estimate of 154.00 and a low estimate of 76.00. According to the current price, Neurocrines is 75.05%. Neurocrine Biosciences and Voyager Therapeutics inked a CNS-targeted collaboration. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health. Examples of growth stocks are pharmaceutical companies. Neurocrine Biosciences employees earn $90,500 annually on average, or $44 per hour. Highest paying job is a Medical Director at $251,000. Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference. Tardive Dyskinesia market is predicted to exhibit remarkable growth during the forecast period (2023-2032), analyzes delveinsight. Neurocrine Biosciences is known for discovering, developing and marketing pharmaceuticals for neurological, endocrine and psychiatric disorders. The biopharmaceutical company focuses on the research and development of drugs for neurological and endocrine disorders.

Stock Profile

"Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."

Keywords

The game is changing. There is a new strategy to evaluate Neurocrine Biosciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Neurocrine Biosciences are: Neurocrine, Biosciences, stock, price, growth, pharmaceutical, company, and the most common words in the summary are: neurocrine, bioscience, stock, inc, data, market, price, . One of the sentences in the summary was: 64 analysts offering price forecasts for Neurocrine Biosciences have a median target of 118.42, with a high estimate of 154.00 and a low estimate of 76.00. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #neurocrine #bioscience #stock #inc #data #market #price.

Read more →

Youtube Subscribe

---